摘要
背景:2019年冠状病毒病(COVID-19)成为近代人类历史上的主要健康问题,全球有成千上万的死亡和数百万例病例。对其他冠状病毒的最新研究和较旧的经验强调了可能与SARS-CoV-2感染的内在作用有关的肾素-血管紧张素系统(RAS)紊乱的潜在机制。 目的:在这篇综述中,我们旨在描述RAS成分,免疫系统和COVID-19病理生理学之间的紧密联系。 方法:这篇非系统性的综述文章总结了有关COVID-19与RAS之间关系的最新证据。 结果:多项研究表明,膜结合ACE2的下调可能对免疫功能受损和COVID-19患者的预后起着关键作用。下调可能通过不同的机制发生,特别是:(1)SARS-CoV-2融合途径诱导的脱落过程,这减少了膜结合的ACE2的数量,高水平的血管紧张素II刺激了更多的脱落; (2)ACE2受体与病毒本身的内吞作用;(3)SARS-CoV-2引起的干扰素抑制作用对免疫系统的影响,导致ACE2受体表达降低。 结论:最近的研究提供了减少替代RAS轴的成分的证据,包括ACE2和血管紧张素-(1-7)。相反,增加的血管紧张素II水平可以激活几个器官中的AT1受体。因此,感染SARS-COV-2的患者发炎,血栓形成和血管生成增加。应主要在新型疫苗和拟用药物的背景下,注意RAS与COVID-19的相互作用。
关键词: COVID-19,SARS-COV-2,RAS,下调,ACE2受体,血管紧张素II,血管紧张素(1-7)。
图形摘要
Current Drug Targets
Title:Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Volume: 22 Issue: 3
关键词: COVID-19,SARS-COV-2,RAS,下调,ACE2受体,血管紧张素II,血管紧张素(1-7)。
摘要:
Background: The Coronavirus Disease 2019 (COVID-19) is becoming the major health issue in recent human history with thousands of deaths and millions of cases worldwide. Newer research and old experience with other coronaviruses highlighted a probable underlying mechanism of disturbance of the renin-angiotensin system (RAS) that is associated with the intrinsic effects of SARS-CoV-2 infection.
Objective: In this review, we aimed to describe the intimate connections between the RAS components, the immune system and COVID-19 pathophysiology.
Methods: This non-systematic review article summarizes recent evidence on the relationship between COVID-19 and the RAS.
Results: Several studies have indicated that the downregulation of membrane-bound ACE2 may exert a key role for the impairment of immune functions and for COVID-19 patients’ outcomes. The downregulation may occur by distinct mechanisms, particularly: (1) the shedding process induced by the SARS-CoV-2 fusion pathway, which reduces the amount of membrane-bound ACE2, stimulating more shedding by the high levels of Angiotensin II; (2) the endocytosis of ACE2 receptor with the virus itself and (3) by the interferon inhibition caused by SARS-CoV-2 effects on the immune system, which leads to a reduction of ACE2 receptor expression.
Conclusion: Recent research provides evidence of a reduction of the components of the alternative RAS axis, including ACE2 and Angiotensin-(1-7). In contrast, increased levels of Angiotensin II can activate the AT1 receptor in several organs. Consequently, increased inflammation, thrombosis and angiogenesis occur in patients infected with SARS-COV-2. Attention should be paid to the interactions of the RAS and COVID-19, mainly in the context of novel vaccines and proposed medications.
Export Options
About this article
Cite this article as:
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology, Current Drug Targets 2021; 22 (3) . https://dx.doi.org/10.2174/1389450121666201020154033
DOI https://dx.doi.org/10.2174/1389450121666201020154033 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nonnucleoside Inhibitors of Adenosine Kinase
Current Pharmaceutical Design Recent Progress Toward Hydrogen Medicine: Potential of Molecular Hydrogen for Preventive and Therapeutic Applications
Current Pharmaceutical Design Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for Pharmacogenomics
Current Pharmaceutical Design Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Current Vascular Pharmacology Evaluation of A Novel GLP-1R Ligand for PET Imaging of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry The Triad: Erectile Dysfunction - Endothelial Dysfunction - Cardiovascular Disease
Current Pharmaceutical Design Exercise and Cardiac Preconditioning Against Ischemia Reperfusion Injury
Current Cardiology Reviews New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Clinical Management of the Cardiovascular Failure in Sepsis
Current Vascular Pharmacology Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19
Endocrine, Metabolic & Immune Disorders - Drug Targets Left Ventricular Non-compaction: From Recognition to Treatment
Current Pharmaceutical Design Hydrogen Sulfide: A New Tool to Design and Develop Drugs
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Structure and Function of Poly(ADP-ribose) Polymerase-1: Role in Oxidative Stress-Related Pathologies
Current Vascular Pharmacology Atrial Fibrillation and Ventricular Tachyarrhythmias: Advancements for Better Outcomes
Cardiovascular & Hematological Disorders-Drug Targets Modulation of Mitochondrial Permeability Transition in Ischemia-Reperfusion Injury of the Heart. Advantages and Limitations
Current Medicinal Chemistry microRNAs: Promising Biomarkers and Therapeutic Targets of Acute Myocardial Ischemia
Current Vascular Pharmacology Progress in Imaging Agents of Cell Apoptosis
Anti-Cancer Agents in Medicinal Chemistry Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology A Survey on Left Ventricle Segmentation Techniques in Cardiac Short Axis MRI
Current Medical Imaging